{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:43:54Z","timestamp":1786999434830,"version":"build-2736575974"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0899823X25000819_as1\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Therapeutic guidelines for\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infections (CDI) were revised a few years ago, promoting the usage of oral vancomycin even for primary mild infections. Vancomycin-resistant enterococci (VRE) is one of the worldwide most significant pathogens. Our study aim was to explore the independent association between oral vancomycin treatment for CDI, and subsequent VRE acquisitions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X25000819_as2\">\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X25000819_as3\">\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>Academic 904-bed general hospital (Shamir Medical Center, Israel).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X25000819_as4\">\n                    <jats:title>Patients:<\/jats:title>\n                    <jats:p>Adult (&gt;18 yr) inpatients with primary CDI and no prior VRE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X25000819_as5\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Study was conducted for calendar years 2016-2020. Logistic regression was used to model-independent predictors for VRE acquisitions. A propensity score (PS)-matched analysis (logistic regression) of the risk of receiving oral vancomycin was conducted to further eliminate potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X25000819_as6\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Overall, 606 patients were included (54% females), with a median age of 75 (IQR = 65\u201385) years. Independent predictors for VRE acquisition were oral vancomycin as a main therapy (aOR = 4.3,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), exposure to systemic vancomycin in the previous 3 months (aOR = 3.2,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), dependent functional status (aOR = 2.3,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006), and diabetes (aOR = 1.8,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04). After controlling for the PS, the independent association between oral vancomycin and later VRE acquisition remained significant in the regression model (aOR = 3.6,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01) and per PS matched-pairs analysis (aOR = 4.4,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X25000819_as7\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Oral vancomycin administered for CDI had a strong independent association with later VRE acquisitions. This finding could promote stewardship interventions in an effort to reduce the usage of oral vancomycin for certain CDI indications, leading to improved CDI management, while curbing the continued emergence of VRE at hospitals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/ice.2025.81","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T05:02:27Z","timestamp":1747371747000},"page":"703-709","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["Usage of oral vancomycin for acute\n                    <i>Clostridioides difficile<\/i>\n                    infection (CDI) resulting in later acquisitions of vancomycin-resistant enterococci (VRE)"],"prefix":"10.1017","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0387-1787","authenticated-orcid":false,"given":"Evgeny","family":"Rogozin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Maree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-1195","authenticated-orcid":false,"given":"Majdi","family":"Masarwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozan","family":"Hasona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herschel T.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Bouganim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6745-4939","authenticated-orcid":false,"given":"Dror","family":"Marchaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"S0899823X25000819_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"S0899823X25000819_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2015.08.005"},{"key":"S0899823X25000819_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.infpip.2024.100413"},{"key":"S0899823X25000819_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2010.10.024"},{"key":"S0899823X25000819_ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1963.03060120024016"},{"key":"S0899823X25000819_ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac435"},{"key":"S0899823X25000819_ref11","doi-asserted-by":"publisher","DOI":"10.1086\/653613"},{"key":"S0899823X25000819_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.09.038"},{"key":"S0899823X25000819_ref16","unstructured":"16. Guidance for laboratory diagnostic of Clostridium difficile infection. Israeli Ministry of Health website. https:\/\/www.gov.il\/BlobFolder\/policy\/bz12-2012\/he\/files_circulars_bz_BZ12_2012.pdf. Published 2012. Accessed March 13, 2025"},{"key":"S0899823X25000819_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa395"},{"key":"S0899823X25000819_ref8","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00936-20"},{"key":"S0899823X25000819_ref14","unstructured":"14. Lewis II, JS . CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition. CLSI; 2024:418."},{"key":"S0899823X25000819_ref17","doi-asserted-by":"publisher","DOI":"10.1086\/519265"},{"key":"S0899823X25000819_ref1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071141"},{"key":"S0899823X25000819_ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02237-17"},{"key":"S0899823X25000819_ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz871"},{"key":"S0899823X25000819_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1085"},{"key":"S0899823X25000819_ref10","unstructured":"10. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Healthimportance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Geneva: World Health Organization; 2024:72."},{"key":"S0899823X25000819_ref2","doi-asserted-by":"publisher","DOI":"10.1038\/srep12666"},{"key":"S0899823X25000819_ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.9045"},{"key":"S0899823X25000819_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198301000-00002"},{"key":"S0899823X25000819_ref13","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2019-0157"},{"key":"S0899823X25000819_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.03.010"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X25000819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T08:21:21Z","timestamp":1752826881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X25000819\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0899823X25000819"],"URL":"https:\/\/doi.org\/10.1017\/ice.2025.81","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}